Candel Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors
'We are delighted to welcome Maha as a new member of Candel's Board,' said Paul Peter Tak, M.D., Ph.D., FMedSci, President and Chief Executive Officer of Candel. 'Her extensive industry experience will be extremely valuable as Candel advances its late-stage oncology programs toward potential approval and commercial development, with the aim of providing benefit to patients with significant unmet need.'
Dr. Radhakrishnan brings significant experience in product development and commercialization that will be particularly valuable as Candel prepares for its Biologics License Application (BLA) submission for CAN-2409 in intermediate-to-high-risk prostate cancer, anticipated in Q4 2026.
'I am honored to join the Board at this pivotal moment as Candel advances its innovative immunotherapy candidates across multiple cancer indications,' said Dr. Radhakrishnan. 'Candel's multimodal approach has the potential to address significant unmet needs in cancers that have historically been difficult to treat with conventional immunotherapies.'
Dr. Radhakrishnan has over 20 years of experience advancing large strategic portfolios across various therapeutic areas through product development and commercialization within major biotechnology and pharmaceutical companies. Since August 2024, Dr. Radhakrishnan has served as an Executive Partner at Sofinnova Investments, a venture capital firm focused on life sciences, where she leads diligence across clinical-ready assets in multiple therapeutic areas and provides expertise to portfolio companies in product development and commercialization. Previously, Dr. Radhakrishnan served as Group Senior Vice President and Chief Medical Officer at Biogen Inc. Earlier in her career, she was Senior Vice President and Global Head of Medical, Primary Care Business Unit at Sanofi S.A. Dr. Radhakrishnan has also held leadership roles at Bioverativ, Inc., Bristol-Myers Squibb Company, UnitedHealth Group, Inc., and Cephalon, Inc. She received her M.D. with honors from the People's Friendship University in Moscow, Russia.
'Maha's expertise will be invaluable as we look forward to her contributions while we prepare to submit our Biologics License Application for CAN-2409 in intermediate-to-high-risk prostate cancer, anticipated in Q4 2026,' said Paul B. Manning, Chairman of Candel's Board.
About Candel Therapeutics
Candel is a clinical-stage biopharmaceutical company focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. Candel has established two clinical-stage multimodal biological immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) gene constructs, respectively. CAN-2409 is the lead product candidate from the adenovirus platform.
The Company recently completed successful phase 2a clinical trials of CAN-2409 in non-small cell lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC), and a pivotal phase 3 clinical trial of CAN-2409 in localized prostate cancer, conducted under a Special Protocol Assessment (SPA) agreed with the U.S. Food and Drug Administration (FDA). CAN-2409 plus prodrug (valacyclovir) has been granted Fast Track Designation by the FDA for the treatment of PDAC, stage III/IV NSCLC in patients who are resistant to first line PD-(L)1 inhibitor therapy and who do not have activating molecular driver mutations or have progressed on directed molecular therapy and localized primary prostate cancer. The FDA also granted Regenerative Medicine Advanced Therapy (RMAT) Designation to CAN-2409 for the treatment of newly diagnosed localized prostate cancer in patients with intermediate-to-high-risk disease and Orphan Drug Designation to CAN-2409 for the treatment of PDAC.
CAN-3110 is the lead product candidate from the HSV platform and is currently in an ongoing phase 1b clinical trial in recurrent high-grade glioma (rHGG). Initial results were published in Nature and CAN-3110 received Fast Track Designation and Orphan Drug Designation from the FDA. Finally, Candel's enLIGHTEN™ Discovery Platform is a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors.
For more information about Candel, visit www.candeltx.com
Forward-Looking Statements
This press release includes certain disclosures that contain 'forward-looking statements,' within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, express or implied statements regarding the timing and advancement of current and future development programs; expectations regarding the submission of the Biologics License Application for CAN-2409 in intermediate-to-high-risk localized prostate cancer; and expectations regarding the therapeutic benefit of the Company's platforms. The words 'may,' 'will,' 'could,' 'would,' 'should,' 'expect,' 'plan,' 'anticipate,' 'intend,' 'believe,' 'estimate,' 'predict,' 'project,' 'potential,' 'continue,' 'target' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, those risks and uncertainties related to the timing and advancement of development programs; expectations regarding the therapeutic benefit of the Company's programs; that final data from the Company's preclinical studies and completed clinical trials may differ materially from reported interim data from ongoing studies and trials; the Company's ability to efficiently discover and develop product candidates; the Company's ability to obtain and maintain regulatory approval of product candidates; the Company's ability to maintain its intellectual property; the implementation of the Company's business model, including strategic plans for the Company's business and product candidates; and other risks identified in the Company's filings with the U.S. Securities and Exchange Commission (SEC), including the Company's most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, each as filed with the SEC and any subsequent filings with the SEC. The Company cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. The Company disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions, or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this press release represent the Company's views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date.
Investor Contact:
Theodore Jenkins
VP, Investor Relations and Business Development
Candel Therapeutics, Inc.
[email protected]
Media Contact:
Ben Shannon
ICR Healthcare
[email protected]
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
10 minutes ago
- Medscape
Rapid Sepsis Test Boosts ED Discharge Rates
TOPLINE: A rapid host response sepsis test, IntelliSep, when implemented early in triage across emergency departments (EDs), led to a significant increase in discharge rates and hospital-free days. METHODOLOGY: Researchers integrated the IntelliSep host response test into the screening of 4650 patients who presented with signs of infection at four EDs in Louisiana and Mississippi between 2024 and 2025. The test measured leukocyte biophysical properties and generated an index (0.1-10.0) from whole blood within 10 minutes. Patients were stratified into three bands on the basis of the risk for sepsis: band 1 (low risk), band 2 (moderate risk), and band 3 (high risk). Screening was conducted through a nurse-driven triage protocol, followed by a physician-driven protocol, with treatment decisions guided by the test result. Outcomes were ED discharge rates, 30-day return visits, and return-adjusted hospital-free days. TAKEAWAY: Based on the test results, 54.8% of patients were classified as low-risk patients (band 1), 25.7% as intermediate-risk patients (band 2), and 19.6% as high-risk patients (band 3). From month 1 to month 4, ED discharge rates increased by 55.9% in patients with low risk (from 22.0% to 34.3%; P < .01) and by 78% in those with intermediate risk (from 10.5% to 18.7%; P < .05). Median return-adjusted hospital-free days increased by 1 day in the overall cohort (from 26.0 to 27.0 days; P < .0001), with a 1-day increase for low-risk patients (from 27.0 to 28.0 days; P < .0001) and a 2-day increase for high-risk patients (from 25.0 to 27.0 days; P < .05). ED return rates remained unchanged across all risk bands throughout the study period. Mortality rates among low-risk patients declined from 10.6% at month 1 to 6.3% at month 4 (P < .05). IN PRACTICE: "Improving quality of care in the ED required our health system to tackle sepsis — a time-sensitive condition that can be deadly if not addressed quickly. Rapid diagnostics like IntelliSep help our team make better treatment decisions," lead author Christopher Thomas, MD, Vice President and Chief Quality Officer at FMOLHS and critical care physician at LSU Health Sciences Center, said in a press release. "By ruling out sepsis for low-risk patients, we're reducing avoidable admissions and creating bed capacity for critically ill patients," the authors wrote. SOURCE: The study was led by Christopher Thomas, MD, Our Lady of the Lake Regional Medical Center, Baton Rouge, Los Angeles. The study was presented at the 2025 Association for Diagnostics & Laboratory Medicine (ADLM) Clinical Lab Expo. LIMITATIONS: The 4-month rollout limits causal inference and long-term insights. Patients with missing discharge disposition data were excluded from the analysis, which may have affected the completeness of the results. DISCLOSURES: One of the study authors is affiliated with Cytovale Inc, the company that developed the IntelliSep test. The authors did not report any funding sources. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Medscape
10 minutes ago
- Medscape
New Lyme Blood Test Bests Standard Diagnostics
A new blood test for Lyme disease outperforms standard diagnostic testing across all stages of the disease, according to new data presented at the 2025 Association for Diagnostics and Laboratory Medicine annual meeting in Chicago. The test, which pairs a multiplexed assay with a machine learning algorithm, showed over 90% accuracy in diagnosing Lyme disease in 308 human serum samples. The CDC estimates that about 476,000 individuals may be diagnosed and treated for Lyme disease each year in the US. The tick-borne disease, caused primarily by infection with Borrelia burgdorferi , is most treatable in the first few weeks of infection, but diagnosis during this early stage poses a challenge to clinicians. Barriers to Early Diagnosis The most common sign of early infection is a skin rash called erythema migrans (EM) that often occurs at the site of the tick bite. While a bull-eye-shaped rash is telltale sign of Lyme disease, this type of EM is actually not a common presentation, said Liz Horn, PhD, MBI, principal investigator of the Lyme Disease Biobank, a biorepository of samples from people with Lyme disease, headquartered in Portland, Oregon. She was not involved with the work. EMs can present in different forms, and about 30% of people with Lyme disease do not develop a rash. 'If you don't have a rash, you have to rely on serologic tests,' Horn said, which are notoriously insensitive in early disease, as antibodies can take weeks to develop. The CDC currently recommends a two-test format. Standard two-tier testing (STTT) involves an enzyme immunoassay as the first step, which, if positive or indeterminate, is followed by a Western Blot. In the first few weeks of disease, antibody levels can be too low to detect, leading to false negatives. In a recent study led by Horn using samples from individuals with signs and symptoms of early Lyme disease who were enrolled in the Lyme Disease Biobank, just 34% of patients presenting with EM > 5 cm tested positive on serologic tests. Among patients without EM, only 16% had positive results, and among those with EM ≤ 5 cm, the positivity rate dropped to just 5%. 'If we could get a serology test that works better in early disease, that could have great benefits for both patients and providers,' Horn said. Pairing AI With a Multiassay This new blood test, called LymeSeek, works differently by detecting 10 different antigens simultaneously. An algorithm developed using deep learning 'sorts through all of the responses,' explained Holly Ahern, MS, MT, the chief scientific officer of ACES Diagnostics, the company developing LymeSeek, in Paradise Valley, Arizona. 'That is what gives the test its very high sensitivity and specificity,' she said. Ahern is also an associate professor of microbiology at State University of New York at Adirondack (SUNY Adirondack) in Queensbury, New York. To validate the test, developers analyzed the human serum samples of 150 control individuals and 158 Lyme disease cases, across all phases of Lyme disease. Samples were provided by the Lyme Disease Biobank, the CDC, and the Johns Hopkins University Lyme Disease Research Center in Baltimore. The control samples were from patients in endemic and nonendemic areas and included individuals with non-Lyme look-like diseases, like mononucleosis and rheumatoid arthritis. The test correctly classified 281 samples as Lyme cases or control individuals, resulting in a test sensitivity of 91.7% and a specificity of 90.7%. In an additional analysis, the ACES diagnostics team also compared LymeSeek to STTT using samples from the Johns Hopkins Lyme Disease Research Center. In very early stages of disease (0-72 hours after appearance of an EM rash), LymeSeek diagnosed 100% of Lyme cases, whereas standard testing identified only 37% of cases. In samples taken 3-4 weeks after EM appearance, LymeSeek's results remained consistent, and standard testing identified 76% of cases. 'The observed seroconversion indicates the enrolled patients did have Lyme disease and is a confirmation that the test result given by LymeSeek is a true positive test result,' Ahern added. In patients with post-treatment Lyme disease (6 months or more after infection), LymeSeek identified 97% of cases, whereas standard testing identified less than half (46%). 'With this one single test, we can detect [Lyme] in the early stages, but we can also detect it across all stages of the disease' Ahern said, which includes through 1 year from first Lyme diagnosis. ACES Diagnostics is now working to develop a clinical trial plan with the FDA. The test has received a De Novo classification, meaning it's being evaluated on its own merits rather than compared to the current standard diagnostics. 'We're not just showing that we are as good as two-tier serology because what's the point of being as good as a test that really isn't very good?' Ahern said.
Yahoo
14 minutes ago
- Yahoo
New Research Reveals Which Simple Health Changes Can Help Prevent Cognitive Decline
A new study suggests that certain lifestyle changes can help keep older adults sharp as they ageNEED TO KNOW A new clinical trial suggests that certain healthy habits can help stave off mental decline in adults as they age The study analyzed the impact of two different two-year lifestyle interventions on over 2,000 older adults at a heightened risk of cognitive decline According to national data cited by researchers, up to 35% of older adults do not meet physical activity guidelines, while 81% have "suboptimal diets"A new study offers more solid evidence that certain healthy behaviors can help stave off mental decline in adults. Habits like improving diet, increasing exercise, monitoring cardiovascular health and experiencing cognitive challenges and social stimulation showed proven benefits in older adults. A clinical trial published on Monday, July 28, by JAMA Network studied the impact of two different two-year lifestyle interventions on 2,111 older adults who had a heightened risk of cognitive decline due to a sedentary lifestyle and poor diet, as well as "at least two additional criteria" linked to their family history of memory issues, higher cardiometabolic risk, race and ethnicity, age and sex. Those randomly assigned to a more structured lifestyle intervention attended 38 peer team meetings over the span of two years, and participated in aerobic, resistance and flexibility workouts. They also received guidelines about eating a healthy Mediterranean diet, completed online cognitive trainings and received specific health coaching from a medical advisor every six months about any abnormal laboratory results. Additionally, they were given monthly rebates of up to $10 for buying blueberries. Meanwhile, those in the self-guided lifestyle intervention group received more general encouragement about exercise, eating well and cognitive and social stimulation "without goal-directed coaching" during six peer team meetings throughout the two years, and were given $75 gift cards to support healthy behavioral changes. Researchers conducted cognitive assessments of the participants during clinic visits at baseline and every six months for two years. "Both interventions promoted increased physical and cognitive activity, healthy diet, social engagement, and cardiovascular monitoring but differed in structure, intensity, and accountability," the study's authors wrote. While researchers found both groups showed cognitive improvement throughout the study, those who participated in the structured intervention "yielded greater benefit" than the self-guided group, they noted. Never miss a story — sign up for to stay up-to-date on the best of what PEOPLE has to offer, from celebrity news to compelling human interest stories. "Among older adults at risk of cognitive decline and dementia, a structured, higher-intensity intervention had a statistically significant greater benefit on global cognition compared with an unstructured, self-guided intervention," the authors added. The findings suggest a large number of people nationwide could benefit long-term by implementing the health changes analyzed in the trial. Its authors note, "National data indicate that up to 35% of older adults do not meet physical activity guidelines, 81% consume suboptimal diets, and nearly 55% meet criteria for metabolic syndrome." Read the original article on People
